BridgeMD
New treatment option for Postpartum Preeclampsia
Official title Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study
ClinicalTrials.gov ID: NCT07185204
What this study is testing
- What it's testing
- The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Pregnant patients ≥ 36 weeks gestation without major fetal anomalies
- Age ≥ 18 years
- Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital
- At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF
- 1 or more high risk factors:
You likely can't join if
- Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to...
- Chronic hypertension, according to ACOG guidelines
- Known allergy or contraindication to nifedipine
- Inability or unwillingness to provide informed consent
- Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)
See the full eligibility criteria
- Pregnant patients ≥ 36 weeks gestation without major fetal anomalies
- Age ≥ 18 years
- Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital
- At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF
- 1 or more high risk factors:
- History of preeclampsia
- Type 1 or 2 diabetes
- Multifetal gestation?
- Renal disease
- Autoimmune disease
- 2 or more moderate risk factors:
- Nulliparity
- BMI \> 30
- First-degree relative with a history of preeclampsia
- African American race
- Low socioeconomic status
- Age \> 35 years
- History of low birthweight or small for gestational age
- Previous adverse pregnancy outcome
- Interpregnancy interval \> 10 years
- Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines
- Chronic hypertension, according to ACOG guidelines
- Known allergy or contraindication to nifedipine
- Inability or unwillingness to provide informed consent
- Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1/PlGF testing (screen failure criteria)
The study team makes the final eligibility decision.
Where it's taking place
- Milwaukee, Wisconsin, United States
- Dhulikhel, Nepal
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Milwaukee, Wisconsin, United States; Dhulikhel, Nepal. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.